InspireMD, Inc. (NSPR) Stock Analysis and Metrics

InspireMD

NASDAQ: NSPR

$0.68 ▼ -0.01 (-1.62%)

At close: Jul 24, 2026 · 3:50 PM UTC

Financial Ratios

Market Cap2,073.45

P/E-0.39

P/S0.00

Div. Yield0.00

Revenue Growth (1y) (Qtr)61.57

Add ratio to table…

About

InspireMD, Inc. is a medical device company focused on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions. Its core offering is the CGuard™ carotid embolic prevention system, which combines a self‑expandable nitinol stent with a proprietary MicroNet™ mesh sleeve to provide embolic protection during carotid artery stenting procedures. The company also markets the next‑generation CGuard Prime stent platform and is advancing the SwitchGuard™ neuroprotection system for transcarotid revascularization.

InspireMD generates revenue primarily from the sale of its CGuard™ and CGuard Prime embolically protected stent systems to hospitals, ambulatory surgery centers, and specialty clinics. Revenue is derived through a network of international distributors that sell the products in Europe, Asia, Latin America, and the United States. The company also receives income from fees associated with clinical study supplies and limited sales of research‑use‑only devices, although the bulk of sales come from commercial stent placements.

InspireMD competes in the carotid artery stenting market against larger, well‑established medical device firms such as Abbott Laboratories, Medtronic plc, and Boston Scientific Corporation. Its competitive advantage lies in the proprietary MicroNet™ technology, which aims to reduce periprocedural stroke risk by capturing embolic debris. The recent U. S. FDA premarket approval for CGuard Prime and CE Mark certification under the EU’s Medical Device Regulation strengthen its regulatory standing and support its claim of offering a best‑in‑class embolic protection solution.

The company’s customer base includes interventional cardiologists, vascular surgeons, neurosurgeons, and the hospitals or catheterization laboratories where these physicians perform carotid artery procedures. InspireMD sells its products through distributors in more than thirty countries, including major markets in Germany, France, Italy, Spain, China, Japan, Brazil, and the United States. While specific customer names are not disclosed in the filing, the revenue base is broadly diversified across geographic regions and institutional accounts.

Investment Thesis

▲ Bull case

The temporary pause in U.S. commercialization for CGuard Prime 135 is a strategic quality enhancement rather than a fundamental flaw, as confirmed by the CEO’s explicit assertion that the action is unrelated to the safety or performance of the CGuard stent implant itself, which continues to demonstrate best-in-class clinical outcomes. This distinction is critical because the core product’s efficacy remains unchallenged, and the company is leveraging its globally proven platform—already used in over 70,000 cases—to secure FDA approval for the original CGuard delivery system by Q3 2026. Once approved, this system will allow immediate reentry into the U.S. market with a product that has substantial real-world validation, eliminating the need for lengthy clinical revalidation and accelerating revenue recovery. The CFO’s commentary further supports this, noting that U.S. customer response to the reintroduction of the original system is expected to be very positive due to prior market receptivity, suggesting pent-up demand could drive a rapid rebound in sales upon relaunch.
The company’s TCAR strategy represents a significant, underappreciated growth catalyst that remains fully on track despite the U.S. delivery system pause, with FDA approval for the CGuard Prime 80 system anticipated in the second half of 2026—a timeline reiterated multiple times by management without qualification. This approval could potentially double the U.S. addressable market by enabling access to transcarotid artery revascularization procedures, a rapidly growing segment of carotid intervention. Moreover, the recent FDA approval to initiate the C-GUARDIANS III trial for the next-generation SwitchGuard neuroprotection system paired with the CGuard Prime 80 positions the company to offer a full, integrated TCAR toolkit upon clearance, creating a differentiated, high-value solution that competitors lack. The CCO’s confirmation that existing customer centers using CGuard Prime will be grandfathered into the original delivery system upon approval further reduces commercial friction, ensuring a seamless transition back to sales growth.
International operations continue to serve as a resilient and growing revenue backbone, with Q1 2026 international revenue increasing 48% year-over-year to $2.2 million, driven by higher unit sales and only partially offset by favorable foreign exchange effects. This performance underscores the global durability of demand for the CGuard implant, which is not contingent on U.S. delivery system performance. The OUS market’s standardization on the original CGuard delivery system means international sales are unaffected by the U.S. voluntary action, providing a stable cash flow foundation to fund R&D and regulatory efforts during the U.S. hiatus. The CEO’s explicit statement that the OUS business will continue to operate as a robust part of the overall story, combined with the CFO’s breakdown showing international revenue as the majority of Q1 totals, highlights that the company is not reliant on U.S. sales for near-term viability, reducing investor concerns about revenue collapse.
Management’s decision to withdraw full-year 2026 guidance reflects prudence rather than weakness, as it allows the company to focus on resolving the delivery system issue without the pressure of misleading forecasts, while maintaining confidence in the long-term trajectory. The CFO’s transparency about expecting no U.S. commercial activity until original CGuard approval in Q3 2026, coupled with the plan to resume sales immediately thereafter, indicates a clear, executable path to revenue restoration. The emphasis on reinvesting in R&D—particularly for the C-GUARDIANS III trial—and pausing headcount investments until regulatory clarity suggests disciplined capital allocation, preserving the $41.6 million cash balance for critical milestones. This approach aligns with the company’s stated philosophy of prioritizing clinical excellence over speed, which could ultimately strengthen market position by ensuring a superior, reliable delivery system upon relaunch.

The temporary pause in U.S. commercialization for CGuard Prime 135 is a strategic quality enhancement rather than a fundamental flaw, as confirmed by the CEO’s explicit assertion that the action is unrelated to the safety or performance of the CGuard stent implant itself, which continues to demonstrate best-in-class clinical outcomes. This distinction is critical because the core product’s efficacy remains unchallenged, and the company is leveraging its globally proven platform—already used in over 70,000 cases—to secure FDA approval for the original CGuard delivery system by Q3 2026. Once approved, this system will allow immediate reentry into the U.S. market with a product that has substantial real-world validation, eliminating the need for lengthy clinical revalidation and accelerating revenue recovery. The CFO’s commentary further supports this, noting that U.S. customer response to the reintroduction of the original system is expected to be very positive due to prior market receptivity, suggesting pent-up demand could drive a rapid rebound in sales upon relaunch.
The company’s TCAR strategy represents a significant, underappreciated growth catalyst that remains fully on track despite the U.S. delivery system pause, with FDA approval for the CGuard Prime 80 system anticipated in the second half of 2026—a timeline reiterated multiple times by management without qualification. This approval could potentially double the U.S. addressable market by enabling access to transcarotid artery revascularization procedures, a rapidly growing segment of carotid intervention. Moreover, the recent FDA approval to initiate the C-GUARDIANS III trial for the next-generation SwitchGuard neuroprotection system paired with the CGuard Prime 80 positions the company to offer a full, integrated TCAR toolkit upon clearance, creating a differentiated, high-value solution that competitors lack. The CCO’s confirmation that existing customer centers using CGuard Prime will be grandfathered into the original delivery system upon approval further reduces commercial friction, ensuring a seamless transition back to sales growth.
International operations continue to serve as a resilient and growing revenue backbone, with Q1 2026 international revenue increasing 48% year-over-year to $2.2 million, driven by higher unit sales and only partially offset by favorable foreign exchange effects. This performance underscores the global durability of demand for the CGuard implant, which is not contingent on U.S. delivery system performance. The OUS market’s standardization on the original CGuard delivery system means international sales are unaffected by the U.S. voluntary action, providing a stable cash flow foundation to fund R&D and regulatory efforts during the U.S. hiatus. The CEO’s explicit statement that the OUS business will continue to operate as a robust part of the overall story, combined with the CFO’s breakdown showing international revenue as the majority of Q1 totals, highlights that the company is not reliant on U.S. sales for near-term viability, reducing investor concerns about revenue collapse.
Management’s decision to withdraw full-year 2026 guidance reflects prudence rather than weakness, as it allows the company to focus on resolving the delivery system issue without the pressure of misleading forecasts, while maintaining confidence in the long-term trajectory. The CFO’s transparency about expecting no U.S. commercial activity until original CGuard approval in Q3 2026, coupled with the plan to resume sales immediately thereafter, indicates a clear, executable path to revenue restoration. The emphasis on reinvesting in R&D—particularly for the C-GUARDIANS III trial—and pausing headcount investments until regulatory clarity suggests disciplined capital allocation, preserving the $41.6 million cash balance for critical milestones. This approach aligns with the company’s stated philosophy of prioritizing clinical excellence over speed, which could ultimately strengthen market position by ensuring a superior, reliable delivery system upon relaunch.

▼ Bear case

The voluntary pause in U.S. commercialization for CGuard Prime 135 signals deeper, unaddressed technical and usability issues with the delivery system that may not be fully resolved by the anticipated early 2027 timeline, despite management’s confidence. The CEO admitted the issues emerged only after broader market engagement during the controlled launch, citing a “learning curve” involving new user experiences and accessory device interactions that were not evident in the limited PMA trial use. This suggests the root cause may involve complex, real-world usability factors that are difficult to predict or fix through standard design iterations, raising the risk of recurrence even after modifications. The CFO’s disclosure of a $700,000 reserve for customer returns and $650,000 for inventory impairment and remediation costs in Q2 2026 indicates tangible financial penalties already being incurred, with no guarantee these costs won’t escalate if remediation takes longer than expected or requires multiple redesign cycles.
The company’s reliance on international sales as a buffer during the U.S. hiatus masks growing vulnerability in overseas markets, where growth is increasingly dependent on favorable foreign exchange rates rather than pure demand strength. While international revenue rose 48% year-over-year in Q1 2026, the CFO explicitly noted that changes in foreign exchange rates contributed 11% to that growth—meaning organic unit-driven expansion was closer to 37%, a figure that may decelerate if currency fluctuations reverse. Furthermore, the OUS market’s dependence on the original CGuard delivery system, while currently stable, does not insulate the company from potential spillover effects if U.S. regulatory delays erode physician confidence globally or if competitors exploit the perception of instability in InspireMD’s product line during this period.
The anticipated FDA approval of the original CGuard delivery system in Q3 2026—cited as the catalyst for U.S. market reentry—carries significant execution risk, as management provided no concrete milestones or data to substantiate this timeline beyond stating discussions are “positive and constructive.” The CFO’s admission that U.S. revenue will remain negligible until this approval, combined with the withdrawal of full-year guidance, implies the company is banking on a regulatory outcome that remains outside its control. Any delay in approval—whether due to additional FDA requests for data, manufacturing concerns, or prioritization of other submissions—would prolong the U.S. revenue vacuum, exacerbating cash burn. With total operating expenses rising to $14.7 million in Q1 2026 (up $2.9 million YoY) and cash reserves declining from $54.2 million to $41.6 million over one year, the current trajectory suggests a cash runway of less than two years at the current burn rate, creating pressure to achieve milestones faster than may be feasible.
The OpEx trajectory during the U.S. commercial pause reveals a misalignment between stated prudence and actual spending, as the CFO acknowledged OpEx will continue to increase slightly due to R&D investments in the C-GUARDIANS III trial, while selling, marketing, and G&A expenses are only expected to be “relatively stable”—not reduced. This suggests the company is not meaningfully cutting costs during the U.S. hiatus, instead maintaining or growing investments in commercial and clinical initiatives that may not generate near-term returns. The decision to pause headcount investment only until regulatory clarity emerges—rather than implementing proactive reductions—further indicates a lack of aggressive cost containment, heightening the risk that cash reserves will be depleted before U.S. sales resume, especially if the CGuard Prime 135 remediation slips into 2028 or later due to unforeseen technical complexities.

The voluntary pause in U.S. commercialization for CGuard Prime 135 signals deeper, unaddressed technical and usability issues with the delivery system that may not be fully resolved by the anticipated early 2027 timeline, despite management’s confidence. The CEO admitted the issues emerged only after broader market engagement during the controlled launch, citing a “learning curve” involving new user experiences and accessory device interactions that were not evident in the limited PMA trial use. This suggests the root cause may involve complex, real-world usability factors that are difficult to predict or fix through standard design iterations, raising the risk of recurrence even after modifications. The CFO’s disclosure of a $700,000 reserve for customer returns and $650,000 for inventory impairment and remediation costs in Q2 2026 indicates tangible financial penalties already being incurred, with no guarantee these costs won’t escalate if remediation takes longer than expected or requires multiple redesign cycles.
The company’s reliance on international sales as a buffer during the U.S. hiatus masks growing vulnerability in overseas markets, where growth is increasingly dependent on favorable foreign exchange rates rather than pure demand strength. While international revenue rose 48% year-over-year in Q1 2026, the CFO explicitly noted that changes in foreign exchange rates contributed 11% to that growth—meaning organic unit-driven expansion was closer to 37%, a figure that may decelerate if currency fluctuations reverse. Furthermore, the OUS market’s dependence on the original CGuard delivery system, while currently stable, does not insulate the company from potential spillover effects if U.S. regulatory delays erode physician confidence globally or if competitors exploit the perception of instability in InspireMD’s product line during this period.
The anticipated FDA approval of the original CGuard delivery system in Q3 2026—cited as the catalyst for U.S. market reentry—carries significant execution risk, as management provided no concrete milestones or data to substantiate this timeline beyond stating discussions are “positive and constructive.” The CFO’s admission that U.S. revenue will remain negligible until this approval, combined with the withdrawal of full-year guidance, implies the company is banking on a regulatory outcome that remains outside its control. Any delay in approval—whether due to additional FDA requests for data, manufacturing concerns, or prioritization of other submissions—would prolong the U.S. revenue vacuum, exacerbating cash burn. With total operating expenses rising to $14.7 million in Q1 2026 (up $2.9 million YoY) and cash reserves declining from $54.2 million to $41.6 million over one year, the current trajectory suggests a cash runway of less than two years at the current burn rate, creating pressure to achieve milestones faster than may be feasible.
The OpEx trajectory during the U.S. commercial pause reveals a misalignment between stated prudence and actual spending, as the CFO acknowledged OpEx will continue to increase slightly due to R&D investments in the C-GUARDIANS III trial, while selling, marketing, and G&A expenses are only expected to be “relatively stable”—not reduced. This suggests the company is not meaningfully cutting costs during the U.S. hiatus, instead maintaining or growing investments in commercial and clinical initiatives that may not generate near-term returns. The decision to pause headcount investment only until regulatory clarity emerges—rather than implementing proactive reductions—further indicates a lack of aggressive cost containment, heightening the risk that cash reserves will be depleted before U.S. sales resume, especially if the CGuard Prime 135 remediation slips into 2028 or later due to unforeseen technical complexities.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password